These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 2208173)

  • 1. Immunocytochemical localization of estrogen and progesterone receptor and prognosis in human primary breast cancer.
    Reiner A; Neumeister B; Spona J; Reiner G; Schemper M; Jakesz R
    Cancer Res; 1990 Nov; 50(21):7057-61. PubMed ID: 2208173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical detection of hormone receptors in breast carcinomas (ER-ICA, PgR-ICA): prognostic usefulness and comparison with the biochemical radioactive-ligand-binding assay (DCC).
    Beck T; Weikel W; Brumm C; Wilkens C; Pollow K; Knapstein PG
    Gynecol Oncol; 1994 May; 53(2):220-7. PubMed ID: 8188083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Steroid hormone receptors in mammary carcinoma. Immunohistochemical detection and prognostic significance].
    Reiner A; Neumeister B; Reiner G; Jakesz R; Kolb R; Schemper M; Spona J
    Zentralbl Pathol; 1991; 137(3):233-41. PubMed ID: 1657132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.
    Viale G; Regan MM; Maiorano E; Mastropasqua MG; Dell'Orto P; Rasmussen BB; Raffoul J; Neven P; Orosz Z; Braye S; Ohlschlegel C; Thürlimann B; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
    J Clin Oncol; 2007 Sep; 25(25):3846-52. PubMed ID: 17679725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype.
    Rakha EA; El-Sayed ME; Green AR; Paish EC; Powe DG; Gee J; Nicholson RI; Lee AH; Robertson JF; Ellis IO
    J Clin Oncol; 2007 Oct; 25(30):4772-8. PubMed ID: 17876012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays.
    Regan MM; Viale G; Mastropasqua MG; Maiorano E; Golouh R; Carbone A; Brown B; Suurküla M; Langman G; Mazzucchelli L; Braye S; Grigolato P; Gelber RD; Castiglione-Gertsch M; Price KN; Coates AS; Goldhirsch A; Gusterson B;
    J Natl Cancer Inst; 2006 Nov; 98(21):1571-81. PubMed ID: 17077359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemically estrogen receptor-negative, progesterone receptor-positive breast carcinoma. Immunocytochemical hormone receptors and prognostic factors.
    Keshgegian AA
    Arch Pathol Lab Med; 1994 Mar; 118(3):240-4. PubMed ID: 8135626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen receptor analysis on biopsies and fine-needle aspirates from human breast carcinoma. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies.
    Reiner A; Spona J; Reiner G; Schemper M; Kolb R; Kwasny W; Függer R; Jakesz R; Holzner JH
    Am J Pathol; 1986 Dec; 125(3):443-9. PubMed ID: 3541638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changing estrogen and progesterone receptor patterns in breast carcinoma during the menstrual cycle and menopause.
    Pujol P; Daures JP; Thezenas S; Guilleux F; Rouanet P; Grenier J
    Cancer; 1998 Aug; 83(4):698-705. PubMed ID: 9708933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical detection of estrogen and progesterone receptors performed with an antigen-retrieval technique on methacarn-fixed paraffin-embedded breast cancer tissues.
    Oyaizu T; Arita S; Hatano T; Tsubura A
    J Surg Res; 1996 Jan; 60(1):69-73. PubMed ID: 8592434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical staining of estrogen and progesterone receptors: aspects for evaluating positivity and defining the cutpoints.
    Jalava P; Kuopio T; Huovinen R; Laine J; Collan Y
    Anticancer Res; 2005; 25(3c):2535-42. PubMed ID: 16080489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
    Hussein MR; Abd-Elwahed SR; Abdulwahed AR
    Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.
    Dowsett M; Allred C; Knox J; Quinn E; Salter J; Wale C; Cuzick J; Houghton J; Williams N; Mallon E; Bishop H; Ellis I; Larsimont D; Sasano H; Carder P; Cussac AL; Knox F; Speirs V; Forbes J; Buzdar A
    J Clin Oncol; 2008 Mar; 26(7):1059-65. PubMed ID: 18227529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interobserver reproducibility of immunocytochemical estrogen- and progesterone receptor status assessment in breast cancer.
    Biesterfeld S; Veuskens U; Schmitz FJ; Amo-Takyi B; Böcking A
    Anticancer Res; 1996; 16(5A):2497-500. PubMed ID: 8917341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
    Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Overgaard J;
    J Clin Oncol; 2008 Mar; 26(9):1419-26. PubMed ID: 18285604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estrogen receptor immunocytochemistry in endometrial carcinoma: a prognostic marker for survival.
    Pertschuk LP; Masood S; Simone J; Feldman JG; Fruchter RG; Axiotis CA; Greene GL
    Gynecol Oncol; 1996 Oct; 63(1):28-33. PubMed ID: 8898164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols.
    Foekens JA; Portengen H; van Putten WL; Peters HA; Krijnen HL; Alexieva-Figusch J; Klijn JG
    Cancer Res; 1989 Nov; 49(21):5823-8. PubMed ID: 2676151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progesterone receptor status provides predictive value for adjuvant endocrine therapy in older estrogen receptor-positive breast cancer patients.
    Yu KD; Liu GY; Di GH; Wu J; Lu JS; Shen KW; Shen ZZ; Shao ZM
    Breast; 2007 Jun; 16(3):307-15. PubMed ID: 17293115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Expression of steroid receptors and DNA synthesis in male breast cancer].
    Petroni S; Mangia A; D'Amico C; Simone G
    Pathologica; 2003 Feb; 95(1):31-6. PubMed ID: 12735283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.